Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis


Cite item

Full Text

Abstract

Aim. To study effects of methotrexate on the titer of antibodies to mutated citrullinated vimentin (anti-MCV) and ascertain possibility of using this marker for control of treatment results and choice of individual effective dose of the drug.
Material and methods. A 12-month trial included 76 patients with verified rheumatoid arthritis (RA). Methotrexate per os was given in a dose 7.5-10 mg/week to 44(57.9%) patients, 25 patients received no basic therapy. Anti-MCV (IU/ml) were detected with commercial chemicals made in Germany (ORGENTEC).
Results. RA patients given methotrexate doses 7.5 and 10 mg/week and untreated with basic anti-inflammatory drugs showed no significant differences by basic clinical and device parameters, level of anti-MCV at primary examination and 12 months later.
Conclusion. Anti-MCV titer cannot be used for control of efficacy of methotrexate treatment in doses 75 and 10 mg/week, choice of individual effective doses.

About the authors

Natal'ya Petrovna Shilkina

Email: shilkin39@mail.ru

Mariya Sergeevna Voronina

Email: knopselgula@rambler.ru

Aleksey Alekseevich Vinogradov

Email: vinograd@fromru.com

Ol'ga L'vovna Borisova

Email: propedevtik@mail.ru

N P Shilkina

State Medical Academy, Yaroslavl

State Medical Academy, Yaroslavl

M S Voronina

State Medical Academy, Yaroslavl

State Medical Academy, Yaroslavl

A A Vinogradov

State Medical Academy, Yaroslavl

State Medical Academy, Yaroslavl

O L Borisova

Municipal hospital , Yaroslavl

Municipal hospital , Yaroslavl

References

  1. Сигидин Я. А., Лукина Г. В. Новые подходы к анализу патогенеза и патогенетической терапии ревматоидного артрита. Науч.-практ. ревматол. 2001; 5: 4-11.
  2. Насонов Е. Л. Почему необходимы ранняя диагностика и лечение ревматоидного артрита? Рус. мед. журн. 2002; 22 (10): 1009-1010.
  3. Ursum J., Nielen M. M., van Schaardenburg D. et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthr. Res. Ther. 2008; 10 (1): R 12.
  4. Bang H., Egerer K., Gauliard A. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthr. and Rheum. 2007; 56 (8): 2503-2511.
  5. Wagner E., Skoumal M., Bayer P. M. et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol. Int. 2009; 28.
  6. Каратеев Д. Е., Лучихина Е. Л., Тюрина Л. Н. и др. Ранняя диагностика ревматоидного артрита в клинической практике на современном этапе (результаты наблюдений за московской когортой больных ранним артритом в рамках программы РАДИКАЛ). Тер. арх. 2008; 5: 8-13.
  7. Roland P. N., Grootenboer Mignot S. et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthr. Res. Ther. 2008; 10 (6): 142.
  8. Klaasen R., Cantaert Т., Wijbrandts С. A. еt al. The relationship between different isotypes (IgM, IgG and IgA) of rheumatoid factor and IgG anticyclic citrullinated peptide antibody and clinical response to infliximab in rheumatoid arthritis. Arthr. and Rheum. 2009; 60: 373-374.
  9. Bobbio-Pallavicini F., Capoorali R., Alpini С. et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 302-307.
  10. Braun-Moscovici Y., Markovits D., Zinder О. et al. Anticyclic citrullinated peptide antibodies as predictor of response to antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J. Rheumatol. 2006; 33: 497-500.
  11. Poter C., Hyrich K. L., Tracey A. et al. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumor necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 2009; 68: 69-74.
  12. Tak P. P., Cohen S. B., Emery P. et al. Baseline autoantibody status (RF, ant-CCP) and clinical response following the first treatment course with rituximab. Arthr. and Rheum. 2006; 54 (9): 368.
  13. Silverman G. J., Schwartzman S., Townsend M. et al. Identification of biomarkers for enhanced benefit to Rituximab in rheumatoid arthritis: role for autoantibodies and inflammatory markers. Arthr. and Rheum. 2009; 60: 628.
  14. Isaacs J. D. et al. Autoantibody-positive RA patients have enhanced clinical response to rituximab when compared with seronegative patients. Ann. Rheum. Dis. 2009; 68 (3): 442.
  15. Mariette X., Kivitz A., Isaacs J. D. et al. Effectiveness of Rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes. Arthr. and Rheum. 2009; 60: S631.
  16. Kang S. Y., Kim M. H. et al. Measurement of inflammatory cytokines in patients with rheumatoid arthritis. Korean J. Lab. Med. 2010; 30 (3): 301-306.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies